Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant

Reference

• Rosenke K, Meade-White K, Letko M, et al. Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection. Emerg Microbes Infect. 2020;9(1):2673–2684.
   PubMed Web of Science ®Google Scholar
• Port JR, Yinda CK, Owusu IO, et al. SARS-CoV-2 disease severity and transmission efficiency is increased for airborne but not fomite exposure in Syrian hamsters. bioRxiv. 2020. 2020.12.28.424565.
   Google Scholar
• Public Health England VTG. SARS-CoV-2 variants of concern and variants under investigation in England, . Public Health England. 2021 11 March 2021; Technical briefing 7.
   Google Scholar
• WHO. COVID-19 Weekly Epidemiological Update, 25 February 2021. Special edition: Proposed working definitions of SARS-CoV-2 Variants of Interest and Variants of Concern. Geneva, Switzerland. 2021
   Google Scholar
• Chen RE, Zhang X, Case JB, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. 2021;27:717–726.
   PubMed Web of Science ®Google Scholar
• Supasa P, Zhou D, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell. 2021;184(8):2201–2211.e7.
   PubMed Web of Science ®Google Scholar
• Stamatatos L, Czartoski J, Wan Y-H, et al. Antibodies elicited by SARS-CoV-2 infection and boosted by vaccination neutralize an emerging variant and SARS-CoV-1. medRxiv. 2021. 2021.02.05.21251182.
   Google Scholar
• Shen X, Tang H, McDanal C, et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe. 2021;29(4):529–539.e3
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Arora P, Groß R, et al. SARS-CoV-2 variants B.1.351 and B.1.1.248: escape from therapeutic antibodies and antibodies induced by infection and vaccination. bioRxiv. 2021. 2021.02.11.430787.
   Google Scholar
• Collier DA, De Marco A, Ferreira IATM, et al. SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies. medRxiv. 2021. 2021.01.19.21249840.
   Google Scholar
• Tegally H, Wilkinson E, Giovanetti M, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv. 2020. 2020.12.21.20248640.
   Google Scholar
• Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3):2000045.
   PubMedGoogle Scholar
• van Doremalen N, Falzarano D, Ying T, et al. Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets. Antiviral Res. 2017;143:30–37.
   PubMed Web of Science ®Google Scholar
• Sia SF, Yan L-M, Chin AWH, et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature. 2020;583(7818):834–838.
   PubMed Web of Science ®Google Scholar
• Mubareka S, Lowen AC, Steel J, et al. Transmission of influenza virus via aerosols and fomites in the Guinea pig model. J Infect Dis. 2009;199(6):858–865.
   Web of Science ®Google Scholar
• Goldman E. Exaggerated risk of transmission of COVID-19 by fomites. Lancet Infect Dis. 2020;20(8):892–893.
   PubMed Web of Science ®Google Scholar
• Pitol AK, Julian TR. Community transmission of SARS-CoV-2 by fomites: risks and risk reduction strategies. medRxiv. 2020. 2020.11.20.20220749.
   Google Scholar
• CDC. How COVID-19 Spreads. 2021.
   Google Scholar
• Zhang R, Li Y, Zhang AL, et al. Identifying airborne transmission as the dominant route for the spread of COVID-19. Proc Natl Acad Sci USA. 2020;117(26):14857–14863.
   PubMed Web of Science ®Google Scholar
• Boone SA, Gerba CP. Significance of fomites in the spread of respiratory and enteric viral disease. Appl Environ Microbiol. 2007;73(6):1687–1696.
   PubMed Web of Science ®Google Scholar
• Yamagishi T. Environmental sampling for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during a coronavirus disease (COVID-19) outbreak aboard a commercial cruise ship. medRxiv. 2020. 2020.05.02.20088567.
   Google Scholar
• Lu J, Gu J, Li K, et al. COVID-19 Outbreak associated with air conditioning in restaurant, Guangzhou, China, 2020. Emerg Infect Dis. 2020;26(7):1628–1631.
   PubMed Web of Science ®Google Scholar
• Hamner L, Dubbel P, Capron I, et al. High SARS-CoV-2 attack rate following exposure at a Choir Practice — Skagit County, Washington, March 2020. MMWR Morb Mortal Wkly Rep. 2020;69(19):606–610.
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu J, Xia H, et al. Neutralizing activity of BNT162b2-elicited serum. N Engl J Med. 2021;384(15):1466–1468.
   PubMed Web of Science ®Google Scholar
• Zhou D, Dejnirattisai W, Supasa P, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera. Cell. 2021;184(9):2348–2361.e6.
   PubMed Web of Science ®Google Scholar
• Planas D, Bruel T, Grzelak L, et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. bioRxiv. 2021. 2021.02.12.430472.
   Google Scholar
• Wang P, Nair MS, Liu L, et al. Antibody Resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593(7857):130–135.
   PubMed Web of Science ®Google Scholar
• Wu K, Werner AP, Moliva JI, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv. 2021. 2021.01.25.427948.
   Google Scholar
• Xie X, Liu Y, Liu J, et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat Med. 2021;27(4):620–621.
   PubMed Web of Science ®Google Scholar
• Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021;27(4):622–625.
   PubMed Web of Science ®Google Scholar
• Tillett RL, Sevinsky JR, Hartley PD, et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis. 2021;21(1):52–58.
   PubMed Web of Science ®Google Scholar
• SeyedAlinaghi S, Oliaei S, Kianzad S, et al. Reinfection risk of novel coronavirus (COVID-19): A systematic review of current evidence. World J Virol. 2020;9(5):79–90.
   PubMedGoogle Scholar
• Lee J-S, Kim SY, Kim TS, et al. Evidence of severe acute respiratory syndrome coronavirus 2 reinfection after recovery from mild coronavirus disease 2019. Clin Infect Dis. 2020;ciaa1421:1058–4838.
   Google Scholar
• Imai M, Iwatsuki-Horimoto K, Hatta M, et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc Natl Acad Sci U S A. 2020;117(28):16587–16595.
   PubMed Web of Science ®Google Scholar
• Selvaraj P, Lien CZ, Liu S, et al. SARS-CoV-2 infection induces protective immunity and limits transmission in Syrian hamsters. Life Sci Alliance. 2021;4(4):e202000886.
   PubMed Web of Science ®Google Scholar
• Clark JJ, Sharma P, Bentley EG, et al. Naturally-acquired immunity in Syrian golden hamsters provides protection from re-exposure to emerging heterosubtypic SARS-CoV-2 variants B.1.1.7 and B.1.351. bioRxiv. 2021.
   Google Scholar
• CDC. Science brief: SARS-CoV-2 and surface (fomite) transmission for indoor community environments. Atlanta, US: CDC. 2021.
   Google Scholar
• Stamatatos L, Czartoski J, Wan Y-H, et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. 2021. eabg9175.
   Web of Science ®Google Scholar
• Zhou D, Dejnirattisai W, Supasa P, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 2021;184(9):2348–2361.e6.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384(20):1885–1898.
   PubMed Web of Science ®Google Scholar